← Back to Screener
Atossa Therapeutics, Inc. Common Stock (ATOS)
Price$6.17
Favorite Metrics
Price vs S&P 500 (26W)-72.76%
Price vs S&P 500 (4W)-0.11%
Market Capitalization$50.20M
All Metrics
Book Value / Share (Quarterly)$4.57
P/TBV (Annual)1.47x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.46
Price vs S&P 500 (YTD)-38.26%
Gross Margin (TTM)62.50%
Net Profit Margin (TTM)-7412.50%
EPS (TTM)$-4.04
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-4.04
EPS (Annual)$-4.04
ROI (Annual)-88.35%
Gross Margin (Annual)100.00%
Cash / Share (Quarterly)$4.80
ROA (Last FY)-73.03%
EBITD / Share (TTM)$-4.31
ROE (5Y Avg)-38.97%
Operating Margin (TTM)-7412.50%
Cash Flow / Share (Annual)$-3.46
P/B Ratio1.28x
P/B Ratio (Quarterly)1.94x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)55.66x
Net Interest Coverage (TTM)-507.00x
ROA (TTM)-57.74%
EPS Incl Extra (Annual)$-4.04
Current Ratio (Annual)5.53x
Quick Ratio (Quarterly)5.03x
3-Month Avg Trading Volume0.12M
52-Week Price Return-35.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
P/S Ratio (Annual)1255.11x
Asset Turnover (Annual)0.00x
52-Week High$19.35
EPS Excl Extra (Annual)$-4.04
CapEx CAGR (5Y)18.13%
Tangible BV CAGR (5Y)123.11%
26-Week Price Return-64.01%
Quick Ratio (Annual)5.03x
13-Week Price Return-35.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.53x
Enterprise Value$8.905
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)51.61%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-30425.00%
Cash / Share (Annual)$4.80
3-Month Return Std Dev106.15%
Net Income / Employee (TTM)$-3
ROE (Last FY)-88.35%
Net Interest Coverage (Annual)-94.50x
EPS Basic Excl Extra (Annual)$-4.04
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.04
Receivables Turnover (Annual)6.30x
ROI (TTM)-65.56%
P/S Ratio (TTM)313.78x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.09
Price vs S&P 500 (52W)-70.82%
Year-to-Date Return-34.12%
5-Day Price Return9.79%
EPS Normalized (Annual)$-4.04
ROA (5Y Avg)-34.82%
Net Profit Margin (Annual)-36650.00%
Month-to-Date Return10.84%
Cash Flow / Share (TTM)$-0.24
EBITD / Share (Annual)$-4.31
Operating Margin (Annual)-30425.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-38.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.04
P/TBV (Quarterly)1.47x
P/B Ratio (Annual)1.94x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-7412.50%
Book Value / Share (Annual)$4.57
Price vs S&P 500 (13W)-38.30%
Beta1.29x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.56%
52-Week Low$3.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ATOSAtossa Therapeutics, Inc. Common Stock | 313.78x | — | 62.50% | — | $6.17 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing treatments for breast cancer and COVID-19. Its lead candidate, Endoxifen, targets breast cancer and related breast conditions. The company also has two COVID-19 programs in development: AT-H201, an inhaled therapy for hospitalized patients, and AT-301, a nasal spray for at-home use.